AU2021245369A1 - Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells - Google Patents

Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells Download PDF

Info

Publication number
AU2021245369A1
AU2021245369A1 AU2021245369A AU2021245369A AU2021245369A1 AU 2021245369 A1 AU2021245369 A1 AU 2021245369A1 AU 2021245369 A AU2021245369 A AU 2021245369A AU 2021245369 A AU2021245369 A AU 2021245369A AU 2021245369 A1 AU2021245369 A1 AU 2021245369A1
Authority
AU
Australia
Prior art keywords
cells
subject
stem cells
subjects
mlpscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021245369A
Other languages
English (en)
Inventor
Silviu Itescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901052A external-priority patent/AU2020901052A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of AU2021245369A1 publication Critical patent/AU2021245369A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021245369A 2020-04-03 2021-04-01 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells Pending AU2021245369A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
AU2020901052 2020-04-03
AU2020901052A AU2020901052A0 (en) 2020-04-03 Method for treating hyperinflammation which comprise administering mesenchymal lineage precursor or stem cells
AU2020901124 2020-04-08
AU2020901124A AU2020901124A0 (en) 2020-04-08 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902312A AU2020902312A0 (en) 2020-07-06 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902312 2020-07-06
AU2020902425A AU2020902425A0 (en) 2020-07-14 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020902425 2020-07-14
AU2020903041 2020-08-25
AU2020903041A AU2020903041A0 (en) 2020-08-25 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020903694 2020-10-12
AU2020903694A AU2020903694A0 (en) 2020-10-12 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
AU2020904312 2020-11-23
AU2020904312A AU2020904312A0 (en) 2020-11-23 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
PCT/EP2021/058683 WO2021198454A1 (en) 2020-04-03 2021-04-01 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
AU2021245369A1 true AU2021245369A1 (en) 2022-11-03

Family

ID=77927537

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021245369A Pending AU2021245369A1 (en) 2020-04-03 2021-04-01 Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells

Country Status (9)

Country Link
US (1) US20230165904A1 (https=)
EP (1) EP4125957A1 (https=)
JP (1) JP2023520233A (https=)
KR (1) KR20220164741A (https=)
CN (1) CN115361959A (https=)
AU (1) AU2021245369A1 (https=)
BR (1) BR112022020042A2 (https=)
CA (1) CA3173216A1 (https=)
WO (1) WO2021198454A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
US12067745B2 (en) 2022-09-27 2024-08-20 Kla Corporation Image pre-processing for overlay metrology using decomposition techniques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CN101511872A (zh) * 2006-08-29 2009-08-19 为人技术株式会社 用于抑制凋亡的药物组合物及其递送方法
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
JP6173157B2 (ja) * 2013-10-02 2017-08-02 日本製薬株式会社 Ｉｌ−１７産生抑制組成物
CN110101873A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 一种利用il-10转基因的干细胞治疗ards的方法
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合

Also Published As

Publication number Publication date
CA3173216A1 (en) 2021-10-07
KR20220164741A (ko) 2022-12-13
BR112022020042A2 (pt) 2022-11-22
JP2023520233A (ja) 2023-05-16
CN115361959A (zh) 2022-11-18
US20230165904A1 (en) 2023-06-01
WO2021198454A1 (en) 2021-10-07
EP4125957A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
US20230165904A1 (en) Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20230104108A1 (en) Method for treating inflammatory bowel disease ii
US20230097931A1 (en) Method for treating chronic graft versus host disease
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20230172991A1 (en) Method for treating inflammatory bowel disease i
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
AU2021403025A1 (en) Method of treating progressive heart failure in subjects with class ii heart failure
WO2023119239A1 (en) Method of treating severe graft versus host disease